Press Release

Morrison & Foerster Represents Japanese Drug Developer Kyowa Hakko Kirin in $272 Million Licensing Deal with Reata Pharmaceuticals, for Kidney Disease Drug


SAN FRANCISCO (January 13, 2010) – Morrison & Foerster represented Japanese drug developer Kyowa Hakko Kirin (Tokyo Stock Exchange: 4151) in the negotiations for a collaboration, supply, and licensing agreement with Texas-based Reata Pharmaceuticals, Inc. that provides Kyowa Hakko Kirin with the exclusive rights to develop, market, and sell Reata’s lead compound, bardoxolone methyl, in Japan and other selected Asian markets.

Upon FDA clearance, bardoxolone will help treat chronic kidney disorder (CKD) and other related diseases. Under the terms of the agreement, Reata retains the rights to develop and commercialize bardoxolone in all other territories not licensed to Kyowa Hakko Kirin, and will receive $132 million in development milestones, including $35 million up front. Reata will also be entitled to receive up to $140 million in sales milestones, as well as royalties from Kyowa Hakko Kirin sales in licensed territories.

Morrison & Foerster partner Jonathan Dickstein negotiated the deal on behalf of Kyowa Hakko Kirin. Mr. Dickstein specializes in licensing, strategic collaborations and other intellectual property-related business transactions. He has represented Kyowa Hakko Kirin in several other negotiations, including a $315 million collaboration deal with pharmaceutical company Sanofi-Aventis Group to develop and commercialize inflammation medication.




Unsolicited e-mails and information sent to Morrison & Foerster will not be considered confidential, may be disclosed to others pursuant to our Privacy Policy, may not receive a response, and do not create an attorney-client relationship with Morrison & Foerster. If you are not already a client of Morrison & Foerster, do not include any confidential information in this message. Also, please note that our attorneys do not seek to practice law in any jurisdiction in which they are not properly authorized to do so.